loading page

VIGICANCER: Understanding “real-world” clinical outcomes in children and adolescents with cancer in Colombia to inform cancer control policy
  • +8
  • Oscar Ramirez,
  • Santiago Bolivar,
  • Vivian Piedrahita,
  • Jesús Ardila,
  • Carlos Portilla,
  • Elvia Karina Grillo Ardila,
  • Maria del Rosario Alvarez,
  • Ximena Castro,
  • Viviana Lotero,
  • Luis Bravo,
  • Paula Aristizabal
Oscar Ramirez
Fundacion POHEMA

Corresponding Author:oramirez@pohema.org

Author Profile
Santiago Bolivar
Pontificia Universidad Javeriana
Author Profile
Vivian Piedrahita
Fundacion POHEMA
Author Profile
Jesús Ardila
Fundacion POHEMA
Author Profile
Carlos Portilla
Fundacion POHEMA
Author Profile
Elvia Karina Grillo Ardila
Fundacion POHEMA
Author Profile
Maria del Rosario Alvarez
Pediatric Hematology/Oncology Unit Hospital Infantil Los Ángeles
Author Profile
Ximena Castro
Fundacion POHEMA
Author Profile
Viviana Lotero
Fundacion POHEMA
Author Profile
Luis Bravo
Universidad del Valle
Author Profile
Paula Aristizabal
University of California San Diego Department of Pediatrics
Author Profile

Abstract

Given scarce data on childhood cancer outcomes in Colombia and discrepancies among hospital-based, population-based, and government registries, we implemented VIGICANCER, a childhood cancer clinical outcomes surveillance system to collect, analyze, and disseminate valid, reliable, and timely data. VIGICANCER has expanded to ten Colombian cities, achieving inclusion of 55-60% of children nationwide. VIGICANCER yields key, exhaustive, and actionable population-based information, guides multilevel interventions, and informs public policy while providing timely feedback to participating institutions. VIGICANCER’s systematic results have positioned our childhood cancer surveillance system as a successful model in Latin America, reproducible in other low–and middle-income countries with similar contexts.
08 Jan 2025Submission Checks Completed
08 Jan 2025Assigned to Editor
08 Jan 2025Submitted to Pediatric Blood & Cancer
09 Jan 2025Review(s) Completed, Editorial Evaluation Pending
12 Jan 2025Reviewer(s) Assigned